Drug Profile
INX 3280
Alternative Names: LR 3280; TA 3280Latest Information Update: 09 Dec 2004
Price :
$50
*
At a glance
- Originator Unknown
- Developer Inex Pharmaceuticals Corporation; Tanabe Seiyaku
- Class Antisense oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lymphoma; Reperfusion injury; Solid tumours
Most Recent Events
- 08 Dec 2004 Discontinued - Preclinical for Reperfusion injury in Japan (unspecified route)
- 17 Jun 2002 Discontinued - Phase-II for Lymphoma in Canada (unspecified route)
- 17 Jun 2002 Discontinued - Phase-II for Solid tumours in Canada (unspecified route)